James Joseph Martin - 28 Oct 2025 Form 4 Insider Report for Cocrystal Pharma, Inc. (COCP)

Role
Co-CEO and CFO
Signature
/s/ James Martin
Issuer symbol
COCP
Transactions as of
28 Oct 2025
Net transactions value
+$15,004
Form type
4
Filing time
30 Oct 2025, 16:15:20 UTC
Previous filing
11 Oct 2024
Next filing
13 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Martin James Joseph Co-CEO and CFO 4400 BISCAYNE BLVD, SUITE # 670, MIAMI /s/ James Martin 30 Oct 2025 0001510224

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COCP Common Stock Award $5,001 +3,598 +8.9% $1.39 44,167 28 Oct 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COCP Warrants Award $10,002 +7,196 $1.39 7,196 28 Oct 2025 Common Stock 7,196 $1.24 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance.
F2 Includes shares of common stock issuable upon vesting of restricted stock units.